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Background: Neuron Glial 2 (NG2) cells are glial cells known to serve as oligodendrocyte progenitors as well as
modulators of the neuronal network. Altered NG2 cell morphology and up-regulation as well as increased shedding
of the proteoglycan NG2 expressed on the cell surface have been described in rodent models of brain injury. Here
we describe alterations in the human NG2 cell population in response to pathological changes characteristic of
Alzheimer’s disease (AD).
Results: Immunohistological stainings of postmortem brain specimens from clinically diagnosed and postmortem
verified AD patients and non-demented controls revealed reduced NG2 immunoreactivity as well as large numbers
of NG2 positive astrocytes in individuals with high amyloid beta plaque load. Since fibrillar amyloid beta (Aβ)1-42 is
the major component of AD-related senile plaques, we exposed human NG2 cells to oligomer- and fibril enriched
preparations of Aβ1-42. We found that both oligomeric and fibrillar Aβ1-42 induced changes in NG2 cell
morphology. Further, in vitro exposure to fibrillar Aβ1-42 decreased the NG2 concentrations in both cell lysates and
supernatants. Interestingly, we also found significantly decreased levels of soluble NG2 in the cerebrospinal fluid
(CSF) from clinically diagnosed AD patients compared to non-demented individuals. Additionally, the CSF NG2
levels were found to significantly correlate with the core AD biomarkers Aß1-42, T-tau and P-tau.
Conclusion: Our results demonstrate major alterations in the NG2 cell population in relation to AD pathology
which highlights the NG2 cell population as a new attractive research target in the search for cellular mechanisms
associated with AD pathogenesis.
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In addition to the three major glial cell types in the brain
i.e. astrocytes, microglia and oligodendrocytes, a fourth
glial cell type, called the NG2 cell, has been shown to
exist. This glial cell is recognized by its stellate morpho-
logy and expression of a specific chondroitin sulphate
proteoglycan. The proteoglycan is called melanoma cell
surface chondroitin sulfate proteoglycan (MSCP) in
humans [1], whilst its homologue in rats is named
Neuron glia 2 (NG2) [1]. The name NG2 cell has been
used to describe the cell type in both species [2]. The
NG2 cell has been extensively studied in rats and has* Correspondence: malin.wennstrom@med.lu.se
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reproduction in any medium, provided the orbeen found to constitute the major group of cells under-
going mitosis in the adult rodent brain, representing
about 5%–8% of all cells in the nervous system [3,4].
Although the NG2 cell population was confirmed to
exist in the human brain already more than twelve years
ago [5], the research field exploring its role within the
human healthy and diseased brain is still in its infancy.
A possible reason for the previous neglect of NG2 cells
as a distinct cell type, may be that NG2 cells can down-
regulate NG2 and differentiate into oligodendrocytes [3]
and thus have long been considered as a mere progeni-
tor cell. However, many of the NG2 cells remain in the
NG2-positive state for a significant time [6], and have a
unique capacity to communicate with nearby cells,
forming multiple contacts with astrocytes, microglia,
oligodendrocytes and neurons [7]. NG2 cells have also
been suggested to regulate neuronal signaling, to stabilizeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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growth [7].
The chondroitin sulphate proteoglycan NG2 (and its
homologue MSPC in humans) expressed on the NG2
cell surface is a type I transmembrane protein with a
core glycoprotein of approximately 300 kDa [1]. The
extracellular domain contains different cleavage sites
and can be shed from the cell surface by proteolytic
cleavage. Approximately half of the NG2 proteoglycan in
the rodent central nerve system (CNS) belong to the
soluble version [8]. The NG2 proteoglycan is not only
found on NG2 cells, but also on infiltrating macrophages
and on pericytes [9-12].
In vitro studies have shown that NG2 cells can become
activated, deactivated or differentiate into reactive astro-
cytes or oligodendrocytes, depending on which factors
(including both cytokines and trophic factors) they are
exposed to [13]. In vivo studies using rodent models
have also demonstrated that NG2 cells retract their
processes, increase the NG2 expression and start to
proliferate in response to severe CNS damage, like stab
wounds or epileptic seizures [8,14,15]. Moreover, a
several-fold increase in soluble NG2 levels has been ob-
served in areas of knife lesioned cerebral rat cortex [8]
and in mice spinal cord experimental autoimmune en-
cephalomyelitis (EAE) [16]. These studies indicate a role
for the NG2 cell and its proteoglycan in reaction to
damage and inflammatory events in the brain. This is
supported by the observed loss of NG2 cells and changes
in NG2 cell morphology that correlate to disease severity
in multiple sclerosis (MS) brain [5,17,18]. In the current
study we have in detail investigated possible alterations
in the human NG2 cell population in response to neuro-
pathology characteristic of Alzheimer’s disease (AD), the
most common cause of neurodegenerative dementia.
In AD progressive neurodegeneration leads to cognitive
decline manifested as dementia. Accumulation and
extracellular deposition of aggregated amyloid-β peptide
(Aβ1-42), so called senile plaques, is one of the key events
in AD pathogenesis with formation of intraneuronal
neurofibrillary tangles (NFTs) of hyperphosphorylated tau
and loss of neurons and synapses as downstream events
[19]. Correlates to these pathological processes can be
monitored in cerebrospinal fluid (CSF), where decreased
levels of Aβ1–42 and elevated levels of phosphorylated-
tau (P-tau) and total tau (T-tau) are indicative of Aβ1–42
deposition, tangle formation and neurodegeneration
respectively [20]. However, not only neurons are affected
in AD. As many as 50% of all AD cases also show loss of
oligodendrocytes and other white matter components, a
condition called white matter disease (WMD) [21,22]. The
underlying cause of oligodendrocyte death has been sug-
gested to include glutamate toxicity [23] and oxidative
stress [24] but also toxic effects of Aβ have been reported.Preclinical studies using stereotaxic injection of Aβ1-42
into rat brain have shown that Aβ can induce extensive
white matter damage and oligodendrocyte death [25]. In
addition, in vitro studies on rat oligodendrocytes have
demonstrated toxic effects of different Aβ fragments
including Aβ1-40 [26], Aβ25-35 [27] and Aβ1-42 [28] as
well as the oligomeric form of Aβ1-42 [30]. Other neuro-
pathological features of AD include neuroinflammation
and activated astrocytes and microglia are commonly
found enwrapping senile plaques in the AD brain. The
finding of these so-called glial nests, together with in vitro
studies demonstrating microglial and astrocytic interna-
lization of Aβ, have led to the conclusion that both astro-
cytes and microglia play important roles in the clearance
and removal of Aβ [30-32].
Thus, AD pathophysiology includes events that theo-
retically affect the NG2 cell population i.e. brain dam-
age, synapse loss, oligodendrocyte loss and gliosis. In
the current study we therefore aimed to investigate the
activity and NG2 shedding of human NG2 cells in
response to components linked to AD pathology. Using
NG2 expressing human primary fetal oligodendrocyte
progenitor cells (from here on called NG2+HOPC) as
a model for human NG2 cells as well as immuno-
histochemical investigations of postmortem brain tis-
sue and quantification of soluble NG2 levels in CSF
from AD patients and non demented controls (ND),
we here for the first time describe alterations in the
human NG2 cell population in response to AD
pathology.Results
NG2 cell characterization in brain tissue from AD patients
and non-demented controls
Characteristics of post-mortem examined individuals
In order to first investigate whether NG2 cells are
affected by AD pathology in the human brain we ana-
lyzed NG2 cells in the molecular layer of hippocampus
(ML) from clinically and postmortem verified AD
patients as well as non-demented (ND) controls. The
demographics of the included subjects are given in
Table 1. To evaluate AD-related neuropathological chan-
ges in the examined individuals we rated the presence of
Aβ deposits and microglia nests in the investigated areas
(Table 2). As expected, three of the clinically diagnosed
AD patient showed extensive plaque load whereas one
clinically diagnosed AD patients showed fewer plaques
compared to the other AD patients. Two of the ND
controls did not exhibit Aβ deposits in ML. Microglial
clustering adjacent to plaques, glial nest formation as
well as changes in microglial morphology were observed
to a higher extent in individuals with high Aβ plaque
load (Table 2).
Table 1 Demographics and characteristics of postmortem examined individuals
NBB (no) Clinical diagnosis Gender (M/F) Age (years) PMDa (hours) Fixation (hours) Braak (NFT) Braak (Aβ) Braak (LB)
2 AD F 71 6.26 24 5 C 0
37 AD F 64 6.44 19 4 C 0
12 AD F 87 6.42 17 4 C 0
78 AD M 83 6.22 16 3 B 0
59 ND F 84 7.65 20 2 B 0
39 ND F 91 4.15 20 1 B 0
49 ND F 83 4.40 14 1 B 0
81 ND M 55 7.30 23 0 0 0
76 ND F 75 6.75 16 1 0 0
NFT = neurofibrillary tangles, LB = Lewy body, AD = Alzheimer’s disease, ND = Non-demented control, PMD = post mortem delay.
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pathology
Next we stained the brain tissue using three different
antibodies directed against NG2 and evaluated
immunohistological staining intensity (IHSI) as well as
morphology of NG2 cells in the ML. The IHSI of NG2
cells varied between individuals and appeared to be
dependent on the NG2 antibody used in the staining
procedure. All three antibodies gave rise to stainings
clearly showing NG2 cells in all ND controls as well as
in one of the AD patients) (Table 2). However, the IHSI
in the remaining three AD patients were either very
weak (when B5 antibody was used (Table 2)) or com-
pletely lost (when antibody clones 9.2.27 and N143.8Table 2 Qualitative assessment of NG2 cell reactivity, Aβ









AD 2 (++++) (++++) (+) R 100
AD 37 (+++) (++++) (++) R 100
AD 12 (++++) (++++) (+) R 100
AD 78 (++) (+) (+++) R 50
ND 59 (++) (++) (++++) r 50
ND 39 (+) (+) (+++++) r 43
ND 49 (+) (+++) (++++) 37
ND 81 - (++) (+++) 5
ND 76 - - (++++) 5
1 Plaque load is indicated either as (−) no Aβ plaques visible, or (+) low (++)
moderate (+++) high and (++++) very high numbers of Aβ plaques.
2 Microglia nests are indicated either as (−) no visible, or (+) low, (++)
moderate and (++++) very high numbers of glial nests.
3 B5 IHSI intensity of NG2 cells is scored as (−) no visible NG2 cells (+) very
weak, (++) weak, (+++) moderate (++++) strong and (+++++) very strong IHSI.
R indicates the presence of more than 50% NG2 cells with reactive
morphology. r indicate the presence of less than 50% reactive NG2 cells.
4 Percentage (%) cells with granular NG2 of total counted cells positive for
NG2.stained with 9.2.27 and N143.8.were used (Figure 1C)). Notably, staining of NG2 on
pericytes in these samples was detectable when all three
NG2 antibodies were used (Figure 1C). When investiga-
ting the NG2 cell morphology we found that NG2 cells
in the ML of the two controls without Aβ deposits
displayed features of resting NG2 cells i.e. multiple
thin, branched processes extending radially from the
cell body (Figure 1A and D), whereas most of the
analyzed NG2 cells in the AD patients displayed fewer,
less branched, shorter processes and swollen cell
bodies (Figure 1B and E and Table 3) indicative of a
reactive state. Controls with Aβ deposits also showed
reactive NG2 cells but to a lesser extent compared to
AD patients (Table 2). The NG2 cells were evenly
distributed and were not found to cluster around Aβ
plaques. The few NG2 cells located nearby plaques
were found to display retracted processes (Figure 1G)
and in rare cases multi-branched processes (data not
shown).
Interestingly, staining using the antibody clones 9.2.27
and N143.8, but not B5, revealed the presence of cells
displaying granular dense aggregates of NG2 (from here
on called granular NG2) (Figure 1F and Additional file 1:
Figure S3). Cells with granular NG2 were found in both
AD patients and ND individuals and the percentage cells
with NG2 of total cells positive for NG2, increased with
Aβ plaque load (Table 2). Further, double immunofluor-
escence staining against NG2 and microglia marker
Iba-1 showed that none of the resting or reactive NG2
cells or cell with granular NG2 were positive for Iba-1
(Figure 2B, 2F-H). However, staining against NG2
(9.2.27 or N143.8) and the astrocytic intrafilament (glial
fibrillary acidic protein (GFAP)) revealed a close co-
localization of granular NG2 with GFAP (Figure 2A, 2C-E
and Additional file 1: Figure S3) and the granular NG2
were often found on one side of the astrocyte. Neither
resting nor reactive NG2 cells were positive for GFAP
(Figure 2C-E).
Figure 1 Microscopic images of NG2 positive cells. A-C show low magnification pictures of brain tissue with (A) resting NG2 cells, (B) reactive
NG2 cells and (C) granular NG2 (arrowhead) as well as pericytes (arrow). D-F show higher magnification images of a resting NG2 cell (D), reactive
NG2 cell (E), granular NG2 (F), G-H show images of reactive NG2 cells (G) and granular NG2 (H) (brown) adjacent to Aβ plaque (purple), (I) shows
Aβ deposits in the investigated hippocampal molecular layer (ML) of an AD patient. Scale bar A-C =150 μm, D-F=10 μm, G, H=25 μm
and I=10 μm.
Table 3 Demographic data of individuals with
antemortem CSF assessment
Characteristics Control (n=36) AD (n=47)
M/F (n) 17 / 19 13 / 34
Age at investigation (yrs) 61 ± 9 *** 77 ± 7
MMSE 28 ± 1 *** 20 ± 4
APOEε4 carriers (%)1,# 31 77
Aβ1–42 (ng/L) 659 ± 230 *** 355 ± 100
T-Tau (ng/L) 279 ± 136 *** 821 ± 322
P-Tau (ng/L)2 47 ± 19 *** 104 ± 39
NG2 (μg/ml)3 1.90 ± 0.07 *1.63 ± 0. 06
Data are presented as mean± SD. 1Data missing on n=2 control. 2 Data
missing on n=2 control, n=10 AD. # Individuals carrying one or two APOEε4
alleles. *** Indicates a significant difference at the p<0.001 level compared to
controls using ANOVA. 3Results are age-adjusted. * Indicates a significant
difference at the p<0.05 level compared to controls using ANCOVA.
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In vitro NG2+HOPC morphology is altered in response to
Aβ1–42
Our postmortem examination revealed changes in NG2
cell morphology in brain areas with high Aβ plaque load.
Since Aβ1–42 is the major component of senile plaques
[20] we aimed to investigate how NG2+HOPC react
upon in vitro exposure to different aggregations forms of
Aβ1–42. Upon exposure to Aβ1–42 oligomer enriched
preparations, NG2+HOPC retracted their processes and
the cell bodies appeared dense (Figure 3A) compared to
cells treated with oligomer vehicle (Figure 3B). Similar
changes were detected also after Aβ1–42 fibril exposure,
slight retraction of processes and more compact cell bodies
(Figure 3C) compared to cells treated with fibril vehicle
(Figure 3D), however not to the same extent as seen after
Aβ1–42 oligomer exposure.
Figure 2 Images of double staining against NG2 (clone 9.2.27)/GFAP and NG2 (clone 9.2.27)/Iba-1. (A) Co-localisation between GFAP+
astrocyte (red) and granular NG2 (green). (B) No co-localisation between iba-1+ microglia (red) and granular NG2 (green). C-E represent images of
an NG2 and GFAP staining in a higher magnification, where (C) shows both ramified (arrow) and clustered (arrowhead) NG2, (D) shows a GFAP+
astrocyte and (E) a merged picture of the two stainings. F-G represent images of NG2 and Iba-1 stainings in a higher magnification where (F)
shows ramified NG2 cells (arrowhead), (G) Iba-1+ microglia and (H) a merged picture of the two stainings. Scale bar A, B=20 μm and C-H=15 μm.
Nielsen et al. Acta Neuropathologica Communications 2013, 1:7 Page 5 of 13
http://www.actaneurocomms.org/content/1/1/7In vitro NG2 concentrations in NG2+HOPC cell lysates and
supernatants decrease in response to Aβ1–42
Results obtained by use of the NG2 enzyme-linked
immunosorbent assay (ELISA) showed significantly re-
duced cell lysate NG2 levels after exposure to both Aβ1–
42 oligomers and fibrils compared to lysates from vehicle
exposed cells (61.86 ± 2.34 μg/ml vs. 42.95 ± 3.69 μg/ml,
p=0.023 and 56.18 ± 3.69 μg/ml vs 35.87 ± 1.945 μg/ml,
p=0.001). Further, a decrease in NG2 levels was found in
cell supernatants from cells exposed Aβ1–42 fibrils
compared to vehicle-treated cells (0.21± 0.090 μg/ml vs
1.29 ± 0.29 μg/ml, p=0.06) (Figure 4).
24 h exposure to Aβ1–42 does not alter NG2+HOPC
viability
To evaluate potential cytotoxic effects of Aβ1–42 oligo-
mers and fibrils on NG2+HOPCs, we measured cell
viability as a function of lactate dehydrogenase (LDH)
activity in the cell culture supernatants. As expected,
cells exposed to the positive control Staurosporineexhibited significantly increased extracellular LDH activity
compared to untreated cells (256.42% more, p<0.001). No
changes were seen after exposure to either Aβ1–42 oligo-
mers or Aβ1–42 fibrils.
Soluble NG2 concentrations in cerebrospinal fluid from
AD patients versus non-demented controls
To investigate if the observed in vitro impact of Aβ1-42
on levels of soluble NG2 is reflected in CSF, we analyzed
CSF from AD patients (n=47) and ND (n=36). The
demographic data, MMSE scores, APOEε4 allele fre-
quency and CSF levels of the well-established AD
biomarkers are found in Table 3. As expected, AD pa-
tients had significantly lower MMSE scores (p<0.001)
and a higher frequency of one or two APOE4 alleles
compared to controls (Table 3). Concentrations of Aβ1–
42 were significantly lower (p<0.001), whereas P-tau
(p<0.001) and T-tau (p<0.001) were significantly higher
in AD patients compared to controls. The AD patient
group was significantly older than the control (p<0.001).
Figure 3 Fluorescence micrographs of NG2+HOPCs stained for
NG2. Images show A) NG2+HOPCs after 18 h exposure to 10 μM
Aβ1–42 oligomers. B) NG2+HOPCs after 18 h exposure to Aβ1–42
oligomer vehicle. C) NG2+HOPCs after 18 h exposure to 10 μM
Aβ1–42 fibrils. D) NG2+HOPCs after 18 h exposure to Aβ1–42 fibril
vehicle Scale bar = 25 μm.
Figure 4 Changes in NG2 levels (% of vehicle) in cell culture
supernatants and cell lysates after exposure to 10μM Aβ1–42
oligomers and 10 μM Aβ1–42 fibrils for 18 h. Each bar represents
the mean ± SEM of 3 independent experiments. Data was analyzed
with paired t-test. * indicates a significant difference at p< 0.05 level
compared to baseline ** indicates a significant difference at p< 0.01
level compared to baseline.
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Since the ND individuals were significantly younger than
the AD patients, we first evaluated whether NG2 CSF
levels were associated with age in the group of ND by
use of correlation analysis. We found a significant cor-
relation between CSF NG2 levels and age in the ND
group (r = 0.532, p=0.001) as well as in AD patients
(r=0.342, p=0.19) and thus age was added as a covariant
in the statistical analyses. Comparison analysis showed
that AD patients had significantly lower levels of NG2 in
the CSF compared to controls (ANCOVA p=0.010).
Graph of NG2 levels, unadjusted for age, are found in
Additional file 2: Figure S4.
Levels of NG2 in CSF correlate with CSF AD biomarkers
To investigate potential associations between NG2 con-
centrations, cognitive decline (mini–mental state exam-
ination (MMSE)) as well as the AD CSF biomarkers
Aβ1–42, T-tau and P-Tau, we used partial correlation
analysis with age as a covariant. We found a correlation
between NG2 levels and Aβ1–42 levels in the AD pa-
tients group (r=0.406, p=0.005). A significant correlation
was also found between P-tau, and NG2 in the control
group (r=0.396, p=0.022) and the AD group (r=0.424,
p=0.01) and between T-tau and NG2 in the control
group (r=0.345, p=0.042) as well as in the AD group
(r=0.352, p=0.016). No links between NG2 levels and
cognitive decline was found in either group and no
significant change in NG2 levels were found when com-
paring males / females or APOEε4 carriers/non-carriers
within the analyzed groups (data not shown). Plotted
graphs of the unadjusted correlations between NG2
levels and Aβ1–42, T-tau and P-tau are found in
Additional file 2: Figure S4.
Discussion
In the current study we show that individuals with high
Aβ plaque load display reduced NG2 immunoreactivity
as well as a high frequency of NG2 positive astrocytes in
the molecular layer of hippocampus. We also found a
significant aggregation-state dependent Aβ1–42 effect
on morphology and NG2 expression/shedding of cul-
tured primary human NG2+HOPC. Further we quanti-
fied the levels of soluble NG2 in the CSF of AD patients
and the ND group and showed that NG2 levels in-
creased with age and that AD patients displayed lower
CSF NG2 levels compared to ND. Last, we found signifi-
cant associations between the well-established AD core
biomarkers and NG2 CSF levels. Taken together our
results clearly demonstrate an impact of AD pathology
on NG2 cell activity and NG2 expression/shedding.
In line with previous studies of brain tissue from
rodents exposed to neuroinflammatory stimuli (such as
stab wounds and epileptic seizures [8,14,15]) and patients
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cerebral ischemia, sepsis and cerebral hemorrhage) [2], we
found reactive NG2 cells in individuals with AD path-
ology. Given our in vitro findings showing morphological
changes after both Aβ1-42 oligomer and fibril exposure, it
is tempting to speculate that the described changes in
NG2 cell morphology in brain tissue might reflect
prolonged exposure to high Aβ1-42 load. However,
although Aβ1-42 to some extent may affect the cell
morphology we cannot exclude the possibility that the
observed changes could be due to the neuroinflammatory
events linked to AD pathology. As in previous studies of
brain tissue from AD patients [33], we found strong glial
activation and presence of glial nests in individuals with
AD pathology. Moreover glial nests increased in number
with pathology severity. The coexistence of reactive
microglia and reactive NG2 cells has been described in
both clinical and preclinical studies [2,34] and NG2 cells
are often found spatially close to microglia [34]. In
addition, in vitro studies have shown that NG2 cells
strongly respond to factors secreted by activated microglia
[35-37] and it has been suggested that the NG2 activation,
induced by microglial activity, occurs at the expense of
NG2 cell differentiation into mature oligodendrocytes
[38,39]. Thus, it is possible that the changed NG2 cell
morphology might reflect a change in cell activation re-
lated to AD pathology-induced neuroinflammation and
microglial activation.
Previous studies have also shown that systemically
administered lipopolysaccharides (LPS) induce expres-
sion of NG2 by microglia [40]. We therefore investigated
potential overlaps between NG2 immunoreactivity and
the microglial specific marker (Iba-1) and found no co-
expression of these two antigens. Based on the lack of
NG2 and Iba-1 overlap, the morphology of the NG2
positive cells (bipolar cell bodies with spine-like perpen-
dicularly branched processes) as well as the difference in
distribution of the two cell types around amyloid
plaques, we conclude that the observed NG2 immunore-
active cells are indeed NG2 cells.
The IHSI of NG2 in three out of four investigated
brains from AD patients was very weak (B5 staining) or
undetectable (9.2.27 and N143.8 staining). Previous stu-
dies have shown that postmortem delay (PMD) and post
fixation duration can affect NG2 immunoreactivity. In
the current study, however, the PMD and post fixation
duration did not differ between AD and ND. Also, due
to the fact that NG2 expressing pericytes were indeed
visible in tissue from these AD patient patients, we would
like to argue that tissue handling was not the underlying
cause of NG2 immunoreactivity loss. Whether absence of
visible NG2 cells resulting from NG2 cell death, differenti-
ation or merely a reduction of detectable NG2 remains to
be investigated, but our in vitro result demonstrating areduction in levels of NG2 in both supernatants and
lysates of NG2+ HOPC cells in the presence of Aβ1-42
are in line with the latter hypothesis.
Interestingly, we also observed cells with NG2 im-
munoreactivity appearing as aggregated NG2 granules
frequently located on one side of the cell nuclei. The
number of these cells appeared to increase with AD
pathology severity and was detected using two different
NG2 antibody clones, 9.2.27 and N143.8, whereas B5
failed to capture granular NG2. Although, the epitope
for N143.8 is known to be located at the membrane
proximal domain 3 of the NG2 core protein [41], less is
known about the epitope location for clone B5 and
9.2.27. However, our study suggests that the granular
NG2 represents fragments of NG2 displaying epitopes
only for clones 9.2.27 and N143.8.
As described before, we found no co-labeling between
the microglia marker Iba-1 and granular NG2, however
staining against the astrocytic intracellular filament
GFAP showed that the large majority of granular NG2
co-localized with GFAP. The co-localization could theor-
etically be due to NG2 cell differentiation into astro-
cytes, astrocytes temporarily expressing NG2, astrocytic
cell surface binding to soluble NG2 or astrocytic NG2
uptake. Indeed there are several rodent studies
suggesting that NG2 cells can generate reactive astro-
cytes at sites of CNS injury [42-46]. However, the fact
that the NG2 granules in our study appeared in clusters
located in restricted areas close to the intrafilament
GFAP and not evenly spread out on the surface of the
astrocytes, speaks in favor of phagocytic activity.
In response to injury NG2 cells not only change
morphology, they also upregulate the expression of NG2
and the amount of soluble NG2 shed into the surround-
ings increases. For instance, several-fold higher levels of
soluble NG2 can be observed in the rat cortex after knife
lesions [8]. Interestingly, we here found that both oligo-
mer and fibril enriched preparations of Aβ1-42 instead
reduced levels of NG2 in NG2+HOPC cell lysates and
that fibrillar, but not oligomeric Aβ1-42, reduced NG2
levels in cell culture supernatants. Since we found no
significant difference in NG2 cell viability upon exposure
to either Aβ1-42 oligomeric or Aβ1-42 fibrillar prepara-
tions, a finding in line with a previous study proposing
an OPC relative resistance to Aβ1-42 toxicity [29], we
suggest that the reduced levels of NG2 are caused by an
aggregation-dependent direct or indirect effect of Aβ1-
42 on shedding and expression, possibly involving both
inhibition of enzymatic shedding and downregulation of
NG2 expression.
The significance of the impact of Aβ1-42 on NG2
levels remains elusive, as literature describing the exact
function of NG2 is scarce. However, lessons learned
from studies within the field of glioma demonstrate that
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activities of integrins or growth factor receptors and
thereby play an important role in NG2 cell motility and
proliferation [47]. Further, results from in vivo studies
suggest an important role of NG2 in neurite outgrowth
[48] and NG2 has been proposed to be involved in the
formation of synapses between NG2 cells and neurons
[49]. It should be noted that our in vitro studies were
performed on cells isolated from fetal white matter.
Thus, although the literature suggests that the perinatal
OPCs react to the same stimuli as postnatal OPC [50]
previous studies have shown differences in certain pro-
perties such as proliferation rate and differentiation fate
[51]. Further, some studies have suggested that the NG2
cell population is heterogeneous [52]. We should there-
fore bear in mind that cells from different brain areas
may respond differently to Aβ exposure.
To investigate whether alterations in NG2 shedding
can be monitored clinically, we analyzed NG2 concen-
trations in CSF from AD patients and ND individuals.
Our results showed that CSF levels of NG2 in both AD
patients and non-demented controls increased with age.
Although a link between NG2 expression and age has
not been properly investigated before, previous studies
on rats have demonstrated age-related changes in NG2
cell proliferation and differentiation. From birth and up
until middle age NG2 cells were shown to proliferate
yielding an increase in the NG2 cell population. With
increasing age, proliferation declines, but so does the
differentiation of NG2 cells into mature oligodendro-
cytes [53]. A recent study on glial cells in the cerebral
cortex from aging primates instead suggested that the
number of oligodendrocytes increase with age and that
the increase is most probably due to NG2 cell prolifera-
tion [54]. Another plausible explanation could be linked
to changes in NG2 cell activity. Microglial activation
increases with age and given the previously discussed
co-activation of these cell types, it is likely that NG2
cells also increase their activation and thereby increase
the NG2 expression.
Our analysis further demonstrated that AD patients
displayed significantly lower NG2 levels in the CSF
compared to healthy elders when age was used as a co-
variant. Whether the observed reduction in NG2 levels
is due to reduced expression, shedding, clearance or
even loss of NG2 cells due to cell death or inhibited
proliferation is yet to be determined. Notably, the ob-
served reduction is in line with the results from our
in vitro studies showing a reduction in NG2 concentra-
tions in response to Aβ1-42 exposure. Moreover, recent
preliminary work by Honeywell and colleagues demon-
strated that a decrease in the NG2 cell population as well
as reduced NG2 levels in the 3xTg-AD mouse model
coincide with increased Aβ levels in brain (abstractpublished in Neuroscience Meeting Planner No. 352.15/
W8. Washington, DC: Society for Neuroscience, 2011).
Importantly, we also found a positive correlation between
the CSF levels of Aβ1-42 and NG2 levels in the investi-
gated AD patients. Since decreased levels of Aβ1-42 in
CSF have been shown to correlate with increased Aβ load
in the brain [55], we suggest that the positive correlation
implies an association between lower Aβ1-42 plaque load
(thus higher CSF Aβ1-42) and higher NG2 levels, and vice
versa, further supporting the hypothesis that Aβ affects
the amount of soluble NG2. Finally, there is to date no
way to determine the cellular origin of the NG2 levels
quantified in the CSF, which complicates the inter-
pretation of reduced CSF NG2 levels as a result of
AD-pathology-related effects on specific NG2 expressing
cell types.
Conclusion
Our described results suggest that the NG2 cell popula-
tion is strongly affected by components involved in AD
pathology. The significance of our findings is underlined
by an increasing number of studies describing NG2 cells
as regulating cells, which tightly communicate with the
neuronal network. Previous studies have also demon-
strated changes in the NG2 cell population in response
to various stimuli known to affect emotional processing
and spatial memory including stress hormones [56],
electroconvulsive seizure (rat model for the antide-
pressant treatment electroconvulsive therapy) [56-58],
lithium [59] and enriched environment [60]. Moreover,
the role of NG2 cell as oligodendrocyte progenitors,
differentiating when re-myelination is needed [30,61],
inevitably leads to the speculation that alterations in this
population pool or even a failure of differentiation due
to microglial activation [38,39] could potentially in part
underlie the oligodendrocyte loss and white matter
damage found in AD patients. We therefore conclude
that our current study, a first step to investigate the acti-
vation state and NG2 expression/shedding of human
NG2 cells in the presence of AD pathology, highlights
the NG2 cell population as an attractive and still rather
unexplored research target in the search for cellular
mechanisms related to AD pathogenesis.
Methods
Postmortem brain tissue studies
Brain tissue
Postmortem human brain tissue was obtained from the
Netherlands Brain Bank (NBB) (project nr 2010/636).
Written informed consent for the use of brain tissue and
clinical data for research purpose was obtained from all
patients or their next of kin. The study included n=4
clinically and postmortem verified AD patients and n=5
ND [62] (see Table 1). One cm thick slices from the
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sected at autopsy within 7 hours postmortem. The tissue
was post fixed in 4% paraformaldehyde for 14–20 hours
and left in phosphate buffered saline (PBS) containing
30% sucrose for 4 days. Sections, 30μm thick, were cut
using a cryostate and stored free floating in antifreeze
cryoprotectant solution at −20°C until analyzed using
immunohistochemistry.Immunohistological stainings
Brain tissue sections were analyzed with immunohis-
tological techniques using the mouse polyclonal anti-
NG2 (1:1, clone B5, ATCC, kind gift from Dr William
Stallcup, ATCC), mouse monoclonal anti-NG2 (1:200,
clone 9.2.27, Millipore), mouse monoclonal anti-NG2
(1:200, clone N143.8, kind gift from Dr William Stallcup)
mouse monoclonal anti-Aβ1-17 (1:400, clone 6E10,
BioSite), rabbit anti-Iba-1 (1:200, Wako) against actin-
linking molecule expressed by macrophages and micro-
glia [63].
Tissue sections were quenched in 3% H2O2 and 10%
methanol for 30 min and incubated in Impress reagent kit
blocking solution (Vector laboratories) for 1 h at RT,
followed by incubation with primary antibodies (anti-
NG2, anti Aβ-1-17, anti-Iba-1) in blocking solution
overnight at 4°C. Sections were thereafter incubated with
appropriate (i.e. either anti-rabbit Igs or anti-mouse Igs)
Impress reagent kit secondary antibodies (Vector Labora-
tories) for 2 h at RT followed by peroxidase detection for
3 min (0.25 mg/ml diaminobenzidine with 0.028% NiCl
and 0.012% H2O2 (brown color) or Nova red (red color)
or VIP (purple color) (Vector Laboratories). Sections were
mounted, dehydrated and cover-slipped. Three sections
from each staining and subject were analyzed with an
Olympus AX70 light microscope equipped with 4 - 40×
objectives. The percentage of cells with granular NG2 of
total number of counted NG2+ cells (approximately 200
cells) in ML was calculated. Activity state of NG2 cells
were estimated based on previously described changes in
NG2 cell morphology (swollen cellbodies, retracted pro-
cesses and increased NG2 immunoreactivity) [14]. Num-
ber of reactive and resting NG2 cells were estimated and
ranked as (R) indicating more than 50% reactive NG2 cells
or (r) indicating less than 50% reactive NG2 cells. Two in-
dependent blinded observers semi-quantitatively scored
the intensity of the immunohistochemical staining (IHSI)
of NG2 as: (−) no visible NG2 cells, (+) weak (++) moder-
ate, (+++) high and (++++) very high IHSI (see Table 2).
Amyloid-beta deposits were semi-quantitatively scored as:
(−) no visible, (+) low number, (++) moderate number and
(++++) very high number of Aβ plaques (see Table 2).
Presence of microglial nests was also semi-quantitatively
scored as: (−) no visible, (+) low number, (++) moderatenumber and (++++) very high number of microglia nests
(see Table 2).
Double immunoflouresence stainings
Tissue sections were incubated with blocking solution
(5% goat serum (Jackson immunoresearch) and 5%
human serum (in house)) for 1 h at RT followed by incu-
bation with mouse anti-NG2 (B5, 9.2.27 and N143.8)
together with either rabbit anti-Iba-1 (1:200, Wako) or
rabbit polyclonal anti-Glial fibrillary acidic protein
(GFAP) (1:400 Dako) in blocking solution overnight at
4°C. Sections were incubated with goat anti-rabbit
Dylight 549 (1:500, Vector laboratories) and goat anti-
mouse Alexa488 (1:500, Invitrogen) and mounted with
Vectashield Set mounting medium containing DAPI
(Vector laboratories). Sections were analyzed using
confocal microscopy.
In vitro NG2+HOPC studies
Cells
Fetal primary human oligodendrocyte precursor cells
(HOPCs) (Sciencell Research Laboratories) were cultured
in cell culture medium (Sciencell Research Laboratories)
supplemented with 10% fetal bovine serum (Gibco), as
recommended by the supplier. Cells were grown as
monolayers in poly-L-lysine (PLL) coated culture flasks in
humified air with 5% CO2 at 37°C until 80–90% confluent.
Prior to experiments the cells were harvested by gentle
scraping, plated in 12 well poly-L-lysine coated plates
(Gibco) and grown until 70% confluent.
Preparation of Aβ oligomer- and fibril enriched
preparations
Oligomer and fibril enriched Aβ1-42 preparations were
generated as previously described [30]. Differences in
Aβ1–42 oligomer and Aβ1–42 fibril constituents of the
two preparations, prior to and upon treatment com-
pletion, were recorded using western blot (WB) as
described before [30] (Additional file 3: Figure S1).
NG2+HOPC treatment
For cell treatment the culture media was removed and
replaced with serum-free media (Sciencell Research
laboratories) containing 10μM oligomeric Aβ1-42 or
10 μM fibrillar Aβ1-42. Cells exposed to DMSO/phenol
red free DMEM (oligomer vehicle) or DMSO/ HCl
(fibril vehicle) were used as baseline controls. Cell treat-
ment was conducted for 18 h at 37°C in 5% CO2, Experi-
ments were performed in duplicates and repeated
independently three times. After treatment the cell
culture supernatants were collected, centrifuged (275× g,
5 min, 4°C), aliquoted and stored at −80°C until used.
The cells were lysed with mammalian Cell Lysis kit
(Sigma-Aldrich) according to manufacturers’ protocol,
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concentrations in the wells with different treatment con-
ditions were determined by the use of the Bradford
(coomassie plus) assay kit (Thermo scientific).
Immunocytoflourescence stainings of NG2+HOPC cultures
Cell culture purity was investigated by staining untreated
cells with mouse anti-NG2 and rabbit anti-PDGF AA
receptor (1:200, Abcam). To investigate morphological
changes upon Aβ1-42 challenge the cells were incubated
with 10 μM oligomeric Aβ1-42 and 10 μM fibrillar Aβ1-
42, and corresponding vehicles for 18 h at 37°C and
thereafter stained with mouse anti-NG2. Each condition
was applied in duplicate and the experiments repeated
independently three times. Staining procedures were as
follows: Cells were fixed with 4% formaldehyde, incu-
bated with blocking solution (PBS containing 1% BSA
(Boehringer Mannheim) and 5% goat serum (Jackson
immunoresearch)) followed by incubations with the
primary antibodies (anti-NG2 and anti-PDGFAAR in
blocking solution) and the secondary antibodies (Alexa
488-conjugated anti-rabbit Igs (1:500 Molecular probes)
and/or Cy3-conjugated anti-mouse Igs (1:500, Jackson
Immunoresearch)), Cells were mounted with Vectashield
Set mounting medium with DAPI (Vector laboratories).
Approximately 94% of the cultured cells (n=200 coun-
ted) expressed NG2. The percentage of PDGF-AAR
positive cells (n=200 counted) was 92%.
NG2 quantification assay
The antibody used in our in house developed assay for
NG2 quantification has previously been shown to
recognize both rat and human NG2 [64-66]. To further
evaluate the antibody we performed immunoprecipita-
tion and western blot of concentrated (speed-vac concen-
trator system), enzymatically digested or undigested
(0.025 U/ml Chondroitinase ABC (Seikagaku) lysates and
culture supernatants of NG2+HOPC cells as well as
pooled human CSF. The immunoprecipitation Kit (Sigma-
Aldrich) was used according to the manufacturer’s in-
structions. Mouse IgG was used as a non-relevant negative
control. The precipitated samples were separated using
3-8% tris-acetate gels (Invitrogen) under reducing condi-
tions. Proteins were transferred to membranes (Highbond
ECL, GE healthcare) using a trans-blot semi-dry transfer
cell (Bio-Rad) at RT for 2.5 hours at 50mA per gel. The
membranes were blocked with 5% skimmed milk in 0.05
PBS-T (Fluka analytical) for 1 h and probed with B5 anti-
NG2 antibodies in blocking solution overnight at 4°C. The
membranes were then incubated with biotinylated rabbit
anti-mouse (1:2000 Dako) in blocking solution for 2 h at
RT followed by incubation with high-sensitive streptavidin
(1:4000, Pierce) for 1 h RT. A smear at approximately
290–400 kDa in wells loaded with undigested lysates andsupernatants from NG2+HOPC as well as the presence of
distinct bands at 300–240 kDa in wells loaded with
digested CSF and NG2+HOPC lysates and supernatants
were in line with previous studies [9,41,67,68] and con-
firmed the specificity of B5 against the NG2 proteoglycan
(see Additional file 4: Figure S2).
The in-house assay for NG2 quantification was developed
using the Mesoscale Discovery (MSD) electrochemilumi-
nescence (ECL) technology employing immunoassay con-
version kits (Mesoscale Discovery). Recombinant rat NG2
protein [69] and samples (NG2+HOPC cell culture super-
natants and lysates, and human CSF) were diluted in PBS
and coated onto MSD multi array plates in duplicate wells
(25μl) and allowed to adhere overnight at 4°C. After rinsing,
wells were incubated with blocking solution (PBS-T
containing 1% BSA and 1% skimmed milk) for 1 h at RT.
After another rinse the wells were incubated with mouse
anti-NG2 (B5) for 2 h at RT on an orbital shaker, followed
by rinsing and incubation with sulfo-Tag goat-anti mouse
Igs (Mesoscale) for 1 h in RT on an orbital shaker.
Resulting ECL signal was quantified using an MSD SEC-
TOR Imager 6000. Signal from wells incubated with CSF
and sulfo-Tag anti-mouse Igs (secondary antibodies) did
not differ from zero standard indicating no antibody-
related unspecific binding. Readings of the duplicate stan-
dards and samples were averaged and NG2 concentrations
determined by interpolation of a 4 parametric curve fit.
The intra- and inter-assay variation coefficients (CV%)
were <10 and <23 and recovery of spiked standards (re-
combinant rat NG2) into CSF was between 92–107%. To
limit the effect of inter-assay variations two controls sam-
ples were included in each run to determine the inter-
assay variability. Detection limit was determined to be
58.81 ng/ml.
Cytotoxicity assay
Cell viability was determined as a measure of lactate
dehydrogenase activity (LDH) in the NG2+HOPC cell
culture supernatants as previously described [70]. Cell
culture supernatants from NG2+HOPC cells treated with
dimetylsulfoxid (DMSO)/phenol red free Dulbecco’s
Modified Eagle Medium (DMEM) (Aβ oligomer vehicle)
and DMSO/ HCL (Aβ fibril vehicles) were used as nega-
tive controls and supernatants from cells treated 18 h
with 1 μM Staurosporine (Sigma-Aldrich) were used as a
positive control for cytotoxicity. Resulting K values were




The studied groups consisted of n=47 clinically diagnosed
AD patients and n=36 ND evaluated at the Memory Clinic
at Skåne University Hospital, Malmö, Sweden. Clinical
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Statistical Manual of Mental Disorders by the American
Psychiatric Association (DSM-IV, 1994) combined with
NINCDS-ADRDA diagnostic criteria [71] for probable
AD. Cognitive status of patients and controls was evalu-
ated using the Mini Mental State Examination [72]. The
CSF AD-biomarkers (Aβ1-42, T-tau, P-tau181) were
analyzed in clinical routine by commercial ELISA kits
(Innogenetics). The study protocol was approved by local
ethics committee of Lund University and conducted in
compliance with the Helsinki declaration of 1975 (revised
in 2000). All individuals gave informed consent to partici-
pate in the study.
Statistical analysis
Statistical analysis was performed using the SPSS software
(version 20.0 for Windows, SPSS Inc., Chicago, IL, USA).
The Kolmogorov–Smirnov test was used to assess normal
distribution and the paired samples t-test was used to
detect significant differences in response to in vitro cell
treatment. Differences in CSF NG2 concentrations were
assessed by the use of ANCOVA (controlling for age),
followed by the LSD post-hoc test. Correlations between
the investigated variables were examined using the Pear-
son correlation test or partial correlation test (controlling
for age). Results are presented as means ± standard devi-
ation. A p < 0.05 was considered significant.
Additional files
Additional file 1: Figure S3. Confocal images showing the
hippocampal molecular layer of an AD patient double stained with the
three different NG2 antibody clones B5, 9.2.27 and N143.8 (green)
together with GFAP (red). Merged images of the respective NG2 antibody
and GFAP are found in the lane far to the right. Scale bar = 25 μm.
Additional file 2: Figure S4. Plots showing A) Unadjusted NG2 levels
in CSF from AD patients and non-demented controls prior to ANCOVA
analysis with age as a covariant (AD=Patients with Alzheimers’s disease,
Ctrl = non-demented controls). B) NG2 levels in CSF from non-demented
controls correlates with age (p=0.001). C) Unadjusted NG2 levels and
Aß1–42 levels in CSF from AD patients prior to partial correlation analysis
with age as a covariant. D) Unadjusted NG2 levels and Total tau (T-Tau)
levels in CSF from AD patients prior to partial correlation analysis with
age as a covariant. E) Unadjusted NG2 levels and hyper-phosphorylated
tau (P-Tau) levels in CSF from AD patients prior to partial correlation
analysis with age as a covariant.
Additional file 3: Figure S1. Oligomer and fibril preparations were
incubated for 24 h in 4 and 37 degrees, respectively. Western blot
analysis seen in (A) demonstrates the Aß1-42 preparations separated
under non-reducing conditions on a 10% Tris-Tricine gel. In (B) the left
picture demonstrates Aß1-42 preparations separated under reducing
condition on a 10% Tris-Tricine gel. The right picture depicts the
molecular profile of the Aß1-42 preparations under reducing condition
on a 10% Tris-Tricine gel found in the NG2+HOPC cell lysates and
supernatants of after 18 h of incubation.
Additional file 4: Figure S2. NG2 western blot analysis of
immunoprecipitated cell lysates and culture supernatants NG2+HOPC at
baseline conditions, and pooled human CSF. +) indicates pre-treatment
with chondroitinase ABC (chABC) –) indicates no chABC pre-treatment.
The western blot shows that the clone B5 mouse anti NG2 antibodyrecognized a smear between 300–420 kDa when analyzing cell lysates of
unstimulated NG2+HOPCs. Upon treatment of the cell lysate with
chondroitinase ABC this smear was absent and only a distinct band at
300 kDa was seen. A smear between approximately 290–420 kDa was
detected when examining cell culture supernatants from unstimulated
cells and additional bands at approximately 240 kDa were seen. Also this
smear was lost after enzymatic treatment and only a band at 290 kDa
and a faint band at 240 kDa could be detected. Human CSF yielded two
NG2 bands visualized at 290 and 240 kDa using western blot, and the
same bands, although fainter, were also seen with enzyme treated
human CSF (Figure 4). A similar detection profile was found when rat CSF
was analyzed (data not shown).
Abbreviations
APOE ε4: Apolipoprotein Eε4; AD: Alzheimer’s disease; Aβ: Amyloid beta;
BSA: Bovine serum albumin; CNS: Central nervous system; CSF: Cerebrospinal
fluid; DMEM: Dulbecco’s modified eagle medium; DMSO: Dimetylsulfoxid;
EAE: Experimental autoimmune encephalomyelitis;
ECL: Electrochemiluminescence; ELISA: Enzyme-linked immunosorbent assay;
GFAP: Glial fibrillary acidic protein; IHSI: Immunohistochemical staining;
LDH: Lactate dehydrogenase activity; LPS: Lipopolysaccarides; ML: Molecular
layer of hippocampus; MMSE: Mini–mental state examination; MS: Multiple
sclerosis; MSD: Mesoscale discovery; MSCP: Melanoma cell surface
chondroitin sulfate proteoglycan; ND: Non-demented controls;
NFT: Neurofibrillary tangles; NG2: Neuron glia 2; NG2+HOPC: NG2 expressing
human oligodendrocyte progenitor cells; OPC: Oligodendrocyte progenitor
cells; PBS: Phosphate buffered saline; PMD: Postmortem delay; P-
tau: Phosphorylated tau; T-tau: Total tau; WMD: White matter disease.
Competing interests
None of the authors have any conflicts of interest including any financial,
personal or other relationships with other people or organizations within
three years of beginning the work submitted that would inappropriately
influence the present work.
Authors’ contributions
HMN contributed to study conception and manuscript preparation, DE
performed the brain tissue studies, UA evaluated the NG2 antibody used in the
NG2 ELISA assay, CO gave technical support for evaluation and development of
NG2 ELISA assay, OH contributed with evaluation of clinical data of patients
included in the CSF study, NBB supplied the brain tissue samples, RV
contributed with preparation of the manuscript, AJMR performed
neuropathological diagnosis of individuals included in the brain tissue study, AB
analyzed immunhistological stainings of brain tissue, LM contributed with
collection of CSF and clinical data of individuals included in the CSF study, MW
contributed with conception, study design, analyzed the data and edited the
manuscript. All authors have been involved in drafting and revising the
manuscript and have given final approval of the version to be published.
Acknowledgements
The authors wish to acknowledge the Swedish Dementia Foundation (MW),
Gamla tjänarinnor (MW), Söderström Königska foundation (MW), Magnus
Bergvall foundation (MW), Kockska foundation (MW), ALF (LM, MW, HMN)
and the Swedish Brain Power (LM) for financially supporting this study. We
also thank Michiel Kooreman (Netherlands Brain Bank, Amsterdam,
Netherland) for excellent technical advice and assistance, Dr Uwe Rauch
(Lund University, Lund, Sweden) for valuable discussions and Dr William
Stallcup (Burnham Institute, La Jolla, CA) for the B5 antibody and the rat NG2
recombinant protein.
Author details
1Department of Clinical Sciences Malmö, Molecular Memory Research Unit,
Lund University, The Wallenberg Laboratory 2nd floor, Inga Marie Nilssons
gata, entrance 53, Skåne University Hospital, 205 02, Malmö, Sweden.
2Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San
Pablo Road, Jacksonville, FL 32224, USA. 3Department of Clinical Sciences
Malmö, Clinical Memory Research Unit, The Memory Clinic at Skåne
University Hospital (SUS), Lund University, 205 02, Malmö, Sweden. 4The
Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam,
The Netherlands. 5Department of Clinical Chemistry, Neuroscience Campus
Nielsen et al. Acta Neuropathologica Communications 2013, 1:7 Page 12 of 13
http://www.actaneurocomms.org/content/1/1/7Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
6Department of Pathology, Neuroscience Campus Amsterdam, VU University
Medical Center, Amsterdam, The Netherlands. 7Department of Pathology,
Lund University, Lund 22224, Sweden.
Received: 28 February 2013 Accepted: 28 February 2013
Published: 9 May 2013
References
1. Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB: The primary
structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol
1991, 114(2):359–371.
2. Staugaitis SM, Trapp BD: NG2-positive glia in the human central nervous
system. Neuron Glia Biol 2009, 5(3–4):35–44. doi:10.1017/
S1740925X09990342.
3. Nishiyama A, Chang A, Trapp BD: NG2+ glial cells: a novel glial cell population
in the adult brain. J Neuropathol Exp Neurol 1999, 58(11):1113–1124.
4. Ong WY, Levine JM: A light and electron microscopic study of NG2
chondroitin sulfate proteoglycan-positive oligodendrocyte precursor
cells in the normal and kainate-lesioned rat hippocampus. Neuroscience
1999, 92(1):83–95. http://www.ncbi.nlm.nih.gov/pubmed/10392832.
5. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD: NG2-positive
oligodendrocyte progenitor cells in adult human brain and multiple
sclerosis lesions. J Neuroscience: Official J Soc Neurosci 2000, 20(17):6404–6412.
6. Nishiyama A: NG2 cells in the brain: a novel glial cell population.
Hum Cell 2001, 14(1):77–82.
7. Butt AM, Hamilton N, Hubbard P, Pugh M, Ibrahim M: Synantocytes: the
fifth element. J Anat 2005, 207(6):695–706. doi:10.1111/j.1469-
7580.2005.00458.x.
8. Asher RA, Morgenstern DA, Properzi F, Nishiyama A, Levine JM, Fawcett JW:
Two separate metalloproteinase activities are responsible for the
shedding and processing of the NG2 proteoglycan in vitro. Mol Cell
Neurosci 2005, 29(1):82–96. doi:10.1016/j.mcn.2005.02.001.
9. Bu J, Akhtar N, Nishiyama A: Transient expression of the NG2
proteoglycan by a subpopulation of activated macrophages in an
excitotoxic hippocampal lesion. Glia 2001, 34(4):296–310.
10. Fiedorowicz A, Figiel I, Zaremba M, Dzwonek K, Oderfeld-Nowak B: The
ameboid phenotype of NG2 (+) cells in the region of apoptotic dentate
granule neurons in trimethyltin intoxicated mice shares antigen
properties with microglia/macrophages. Glia 2008, 56(2):209–222.
doi:10.1002/glia.20605.
11. Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH: NG2 is a major
chondroitin sulfate proteoglycan produced after spinal cord injury and is
expressed by macrophages and oligodendrocyte progenitors.
J Neuroscience: Official J Soc Neurosci 2002, 22(7):2792–2803. http://www.
ncbi.nlm.nih.gov/pubmed/11923444.
12. Ozerdem U, Monosov E, Stallcup WB: NG2 proteoglycan expression by
pericytes in pathological microvasculature. Microvasc Res 2002,
63(1):129–134. doi:10.1006/mvre.2001.2376.
13. Nishiyama A: Glial progenitor cells in normal and pathological states.
Keio J Med 1998, 47(4):205–208.
14. Ong WY, Mackie K: A light and electron microscopic study of the CB1
cannabinoid receptor in the primate spinal cord. J Neurocytol 1999, 28(1):39–45.
15. Reynolds R, Cenci di Bello I, Dawson M, Levine J: The response of adult
oligodendrocyte progenitors to demyelination in EAE. Prog Brain Res
2001, 132:165–174.
16. Moransard M, Dann A, Staszewski O, Fontana A, Prinz M, Suter T: NG2
expressed by macrophages and oligodendrocyte precursor cells is
dispensable in experimental autoimmune encephalomyelitis. Brain:
J Neurology 2011, 134(Pt 5):1315–1330. doi:10.1093/brain/awr070.
17. Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D,
Levine J: The response of NG2-expressing oligodendrocyte progenitors
to demyelination in MOG-EAE and MS. J Neurocytol 2002, 31(6–7):523–536.
18. Wilson HC, Scolding NJ, Raine CS: Co-expression of PDGF alpha receptor
and NG2 by oligodendrocyte precursors in human CNS and multiple
sclerosis lesions. J Neuroimmunol 2006, 176(1–2):162–173. doi:10.1016/j.
jneuroim.2006.04.014.
19. Hardy JA, Higgins GA: Alzheimer’s disease: the amyloid cascade
hypothesis. Science 1992, 256(5054):184–185.
20. Zetterberg H, Mattsson N, Shaw LM, Blennow K: Biochemical markers in
Alzheimer’s disease clinical trials. Biomark Med 2010, 4(1):91–98.21. Brun A, Englund E: A white matter disorder in dementia of the Alzheimer
type: a pathoanatomical study. Ann Neurol 1986, 19(3):253–262.
doi:10.1002/ana.410190306.
22. Englund E, Brun A: White matter changes in dementia of Alzheimer’s
type: the difference in vulnerability between cell compartments.
Histopathology 1990, 16(5):433–439.
23. Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity and
disease. Ann N Y Acad Sci 2008, 1144:97–112. doi:10.1196/annals.1418.005.
24. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P: Oxidative
stress: emerging mitochondrial and cellular themes and variations in
neuronal injury. J Alzheimer’s Dis: JAD 2010, 20(Suppl 2):S453–S473.
doi:10.3233/JAD-2010-100321.
25. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG: Amyloid beta peptide-
induced corpus callosum damage and glial activation in vivo.
Neuroreport 2003, 14(11):1429–1433. doi:10.1097/01.wnr.0000086097.47480.a0.
26. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY: Amyloid-
beta peptides are cytotoxic to oligodendrocytes. J Neuroscience: Official
J Soc Neurosci 2001, 21(1):RC118.
27. Takao T, Flint N, Lee L, Ying X, Merrill J, Chandross KJ: 17beta-estradiol
protects oligodendrocytes from cytotoxicity induced cell death. J
Neurochem 2004, 89(3):660–673. doi:10.1111/j.1471-4159.2004.02370.x.
28. Roth AD, Ramirez G, Alarcon R, Von Bernhardi R: Oligodendrocytes
damage in Alzheimer’s disease: beta amyloid toxicity and inflammation.
Biol Res 2005, 38(4):381–387.
29. Horiuchi M, Maezawa I, Itoh A, Wakayama K, Jin LW, Itoh T, Decarli C:
Amyloid beta1-42 oligomer inhibits myelin sheet formation in vitro.
Neurobiol Aging 2012, 33(3):499–509. doi:10.1016/j.neurobiolaging.
2010.05.007.
30. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R:
Astrocytic A beta 1–42 uptake is determined by A beta-aggregation
state and the presence of amyloid-associated proteins. Glia 2010,
58(10):1235–1246. doi:10.1002/glia.21004.
31. Nielsen HM, Veerhuis R, Holmqvist B, Janciauskiene S: Binding and
uptake of A beta1-42 by primary human astrocytes in vitro. Glia 2009,
57(9):978–988. doi:10.1002/glia.20822.
32. Sokolowski JD, Mandell JW: Phagocytic clearance in neurodegeneration.
Am J Pathol 2011, 178(4):1416–1428. doi:10.1016/j.ajpath.2010.12.051.
33. Brunnstrom H, Englund E: Comparison of four neuropathological scales
for Alzheimer’s disease. Clin Neuropathol 2011, 30(2):56–69.
34. Nishiyama A, Yu M, Drazba JA, Tuohy VK: Normal and reactive NG2+ glial cells
are distinct from resting and activated microglia. J Neurosci Res 1997, 48(4):
299–312. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=9169856.
35. Paintlia MK, Paintlia AS, Khan M, Singh I, Singh AK: Modulation of
peroxisome proliferator-activated receptor-alpha activity by N-acetyl
cysteine attenuates inhibition of oligodendrocyte development in
lipopolysaccharide stimulated mixed glial cultures. J Neurochem 2008,
105(3):956–970. doi:10.1111/j.1471-4159.2007.05199.x.
36. Pang Y, Campbell L, Zheng B, Fan L, Cai Z, Rhodes P: Lipopolysaccharide-
activated microglia induce death of oligodendrocyte progenitor cells
and impede their development. Neuroscience 2010, 166(2):464–475.
doi:10.1016/j.neuroscience.2009.12.040.
37. Wu J, Yoo S, Wilcock D, Lytle JM, Leung PY, Colton CA, Wrathall JR:
Interaction of NG2(+) glial progenitors and microglia/macrophages from
the injured spinal cord. Glia 2010, 58(4):410–422. doi:10.1002/glia.20932
38. Defaux A, Zurich MG, Honegger P, Monnet-Tschudi F: Minocycline
promotes remyelination in aggregating rat brain cell cultures after
interferon-gamma plus lipopolysaccharide-induced demyelination.
Neuroscience 2011, 187:84–92. doi:10.1016/j.neuroscience.2011.04.053.
39. Di Bello IC, Dawson MR, Levine JM, Reynolds R: Generation of
oligodendroglial progenitors in acute inflammatory demyelinating
lesions of the rat brain stem is associated with demyelination rather
than inflammation. J Neurocytol 1999, 28(4–5):365–381.
40. Gao Q, Lu J, Huo Y, Baby N, Ling EA, Dheen ST: NG2, a member of
chondroitin sulfate proteoglycans family mediates the inflammatory
response of activated microglia. Neuroscience 2010, 165(2):386–394.
doi:10.1016/j.neuroscience.2009.10.022.
41. Fang X, Burg MA, Barritt D, Dahlin-Huppe K, Nishiyama A, Stallcup WB:
Cytoskeletal reorganization induced by engagement of the NG2
proteoglycan leads to cell spreading and migration. Mol Biol Cell 1999,
10(10):3373–3387.
Nielsen et al. Acta Neuropathologica Communications 2013, 1:7 Page 13 of 13
http://www.actaneurocomms.org/content/1/1/742. Alonso G: NG2 proteoglycan-expressing cells of the adult rat brain:
possible involvement in the formation of glial scar astrocytes following
stab wound. Glia 2005, 49(3):318–338. doi:10.1002/glia.20121.
43. Horky LL, Galimi F, Gage FH, Horner PJ: Fate of endogenous stem/
progenitor cells following spinal cord injury. J Comp Neurol 2006,
498(4):525–538. doi:10.1002/cne.21065.
44. Leoni G, Rattray M, Butt AM: NG2 cells differentiate into astrocytes in
cerebellar slices. Mol Cell Neurosci 2009, 42(3):208–218. doi:10.1016/j.
mcn.2009.07.007.
45. Tatsumi K, Haga S, Matsuyoshi H, Inoue M, Manabe T, Makinodan M,
Wanaka A: Characterization of cells with proliferative activity after a brain
injury. Neurochem Int 2005, 46(5):381–389. doi:10.1016/j.neuint.2004.12.007.
46. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD: NG2 glia
generate new oligodendrocytes but few astrocytes in a murine
experimental autoimmune encephalomyelitis model of demyelinating
disease. J Neuroscience: Official J Soc For Neurosci 2010, 30(48):16383–16390.
doi:10.1523/JNEUROSCI.3411-10.2010.
47. Stallcup WB, Huang FJ: A role for the NG2 proteoglycan in glioma
progression. Cell Adh Migr 2008, 2(3):192–201.
48. Karram K, Chatterjee N, Trotter J: NG2-expressing cells in the nervous
system: role of the proteoglycan in migration and glial-neuron
interaction. J Anat 2005, 207(6):735–744. doi:10.1111/j.1469-
7580.2005.00461.x.
49. Stegmuller J, Werner H, Nave KA, Trotter J: The proteoglycan NG2 is
complexed with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors by the PDZ glutamate receptor interaction
protein (GRIP) in glial progenitor cells. Implications for glial-neuronal
signaling. J Biol Chem 2003, 278(6):3590–3598. doi:10.1074/jbc.M210010200.
50. Kucharova K, Chang Y, Boor A, Yong VW, Stallcup WB: Reduced
inflammation accompanies diminished myelin damage and repair in the
NG2 null mouse spinal cord. J Neuroinflammation 2011, 8:158. doi:10.1186/
1742-2094-8-158.
51. Zhu X, Hill RA, Dietrich D, Komitova M, Suzuki R, Nishiyama A: Age-
dependent fate and lineage restriction of single NG2 cells. Development
2011, 138(4):745–753. doi:10.1242/dev.047951.
52. Bouslama-Oueghlani L, Wehrle R, Sotelo C, Dusart I: Heterogeneity of
NG2-expressing cells in the newborn mouse cerebellum. Dev Biol 2005,
285(2):409–421. doi:10.1016/j.ydbio.2005.07.003.
53. Psachoulia K, Jamen F, Young KM, Richardson WD: Cell cycle dynamics of
NG2 cells in the postnatal and ageing brain. Neuron Glia Biol 2009,
5(3–4):57–67. doi:10.1017/S1740925X09990354.
54. Peters A, Verderosa A, Sethares C: The neuroglial population in the
primary visual cortex of the aging rhesus monkey. Glia 2008,
56(11):1151–1161. doi:10.1002/glia.20686.
55. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS,
Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR
Jr: Transforming cerebrospinal fluid Abeta42 measures into calculated
Pittsburgh Compound B units of brain Abeta amyloid. Alzheimer’s &
dementia: J Alzheimer’s Assoc 2011, 7(2):133–141. doi:10.1016/j.
jalz.2010.08.230.
56. Wennstrom M, Hellsten J, Ekstrand J, Lindgren H, Tingstrom A:
Corticosterone-induced inhibition of gliogenesis in rat hippocampus is
counteracted by electroconvulsive seizures. Biol Psychiatry 2006,
59(2):178–186. doi:10.1016/j.biopsych.2005.08.032.
57. Wennstrom M, Hellsten J, Ekdahl CT, Tingstrom A: Electroconvulsive seizures
induce proliferation of NG2-expressing glial cells in adult rat hippocampus.
Biol Psychiatry 2003, 54(10):1015–1024. doi:S0006322303006930.
58. Wennstrom M, Hellsten J, Tingstrom A: Electroconvulsive seizures induce
proliferation of NG2-expressing glial cells in adult rat amygdala.
Biol Psychiatry 2004, 55(5):464–471. doi:10.1016/j.biopsych.2003.11.011.
59. Orre K, Wennstrom M, Tingstrom A: Chronic lithium treatment decreases
NG2 cell proliferation in rat dentate hilus, amygdala and corpus
callosum. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):503–510.
doi:10.1016/j.pnpbp.2009.01.015.
60. Komitova M, Perfilieva E, Mattsson B, Eriksson PS, Johansson BB: Enriched
environment after focal cortical ischemia enhances the generation of
astroglia and NG2 positive polydendrocytes in adult rat neocortex. Exp
Neurol 2006, 199(1):113–121. doi:10.1016/j.expneurol.2005.12.007.
61. Islam MS, Tatsumi K, Okuda H, Shiosaka S, Wanaka A: Olig2-expressing
progenitor cells preferentially differentiate into oligodendrocytes incuprizone-induced demyelinated lesions. Neurochem Int 2009,
54(3–4):192–198. doi:10.1016/j.neuint.2008.10.011.
62. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P,
Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K,
O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ,
Scheltens P: Research criteria for the diagnosis of Alzheimer’s disease:
revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6(8):734–746.
http://www.ncbi.nlm.nih.gov/pubmed/17616482.
63. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S: A novel gene iba1 in the major
histocompatibility complex class III region encoding an EF hand protein
expressed in a monocytic lineage. Biochem Biophys Res Commun 1996,
224(3):855–862. doi:10.1006/bbrc.1996.1112.
64. Joo NE, Watanabe T, Chen C, Chekenya M, Stallcup WB, Kapila YL: NG2, a
novel proapoptotic receptor, opposes integrin alpha4 to mediate anoikis
through PKCalpha-dependent suppression of FAK phosphorylation.
Cell Death Differ 2008, 15(5):899–907. doi:10.1038/cdd.2008.22.
65. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D,
Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell
markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas
neoplasms of stem cells? Mol Med 2007, 13(3–4):160–165. http://www.ncbi.
nlm.nih.gov/pubmed/17592550.
66. Wen Y, Makagiansar IT, Fukushi J, Liu FT, Fukuda MN, Stallcup WB:
Molecular basis of interaction between NG2 proteoglycan and galectin-3.
J Cell Biochem 2006, 98(1):115–127. doi:10.1002/jcb.20768.
67. Nishiyama A, Dahlin KJ, Stallcup WB: The expression of NG2 proteoglycan
in the developing rat limb. Development 1991, 111(4):933–944.
68. Stallcup WB, Dahlin-Huppe K: Chondroitin sulfate and cytoplasmic
domain-dependent membrane targeting of the NG2 proteoglycan
promotes retraction fiber formation and cell polarization. J Cell Sci 2001,
114(Pt 12):2315–2325.
69. Tillet E, Ruggiero F, Nishiyama A, Stallcup WB: The membrane-
spanning proteoglycan NG2 binds to collagens V and VI through the
central nonglobular domain of its core protein. J Biol Chem 1997,
272(16):10769–10776.
70. Korzeniewski C, Callewaert DM: An enzyme-release assay for natural
cytotoxicity. J Immunol Methods 1983, 64(3):313–320.
71. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH,
Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor
MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The
diagnosis of dementia due to Alzheimer’s disease: recommendations
from the National Institute on Aging-Alzheimer’s Association workgroups
on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia: J
Alzheimer’s Assoc 2011, 7(3):263–269. doi:10.1016/j.jalz.2011.03.005.
72. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975, 12(3):189–198. http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1202204.
doi:10.1186/2051-5960-1-7
Cite this article as: Nielsen et al.: NG2 cells, a new trail for Alzheimer’s
disease mechanisms?. Acta Neuropathologica Communications 2013 1:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
